Investor Presentation

91 Investor presentation First six months of 2022 NASH is a progressive disease with no existing treatment and low diagnosis rates today NASH-Cirrhosis F4 NASH F3 NASH F2 NASH F1 Inflamed tissue Large lipid droplets Inflamed/dying hepatocyte Collagen fibres Inflamed/dying hepatocyte Excessive collagen deposition Dead cell remnants Scar tissue Diagnosis rates Treatment rates Source: Novo Nordisk estimates 26% 32% 42% 50% 70% 90% Novo NordiskⓇ

View entire presentation